#1 Clinical Trials Search in Europe

Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

↓

Matched clinical trials

  • Study on Pembrolizumab for Patients with Early Triple-Negative Breast Cancer Responding Well to Initial Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France

  • Study of Atezolizumab, Carboplatin, and Nab-Paclitaxel for Patients with Metastatic Triple-Negative PD-L1 Positive Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy

  • Study of Datopotamab Deruxtecan for Patients with Triple-Negative Breast Cancer and New or Worsening Brain Metastases

    Recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Ireland

  • Study on NECVAX-NEO1 and Paclitaxel Albumin-Bound for Patients with Triple-Negative Breast Cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany

  • Study of Atezolizumab, Vinorelbine, and Cyclophosphamide for Patients with Advanced Triple Negative Breast Cancer Previously Treated with Anti-PD-L1/PD-1

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy

  • Study of Capecitabine and Pembrolizumab for Patients with Triple Negative Breast Cancer After Chemoimmunotherapy and Surgery

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Study on the Safety and Effects of Farletuzumab Ecteribulin for Patients with Ovarian, Breast, Endometrial, and Lung Cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Spain

  • Study on Pembrolizumab with Chemotherapy for Early-Stage Triple-Negative Breast Cancer in Patients with High TILs

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Portugal

  • Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    Germany

  • Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

    Recruiting

    2 1 1 1
    Investigated Drugs:
    France Spain